BR112019012972B1 - Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos - Google Patents

Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos Download PDF

Info

Publication number
BR112019012972B1
BR112019012972B1 BR112019012972-3A BR112019012972A BR112019012972B1 BR 112019012972 B1 BR112019012972 B1 BR 112019012972B1 BR 112019012972 A BR112019012972 A BR 112019012972A BR 112019012972 B1 BR112019012972 B1 BR 112019012972B1
Authority
BR
Brazil
Prior art keywords
compound
fact
solvent
reaction mixture
formula
Prior art date
Application number
BR112019012972-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112019012972A2 (pt
Inventor
Ana Maria Garcia Collazo
Wolter ten Hoeve
Johannes Nicolaas Koek
Johannes B.M. Rewinkel
Sander DE WILDE
Original Assignee
Minoryx Therapeutics S.L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S.L filed Critical Minoryx Therapeutics S.L
Publication of BR112019012972A2 publication Critical patent/BR112019012972A2/pt
Publication of BR112019012972B1 publication Critical patent/BR112019012972B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BR112019012972-3A 2016-12-23 2017-12-22 Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos BR112019012972B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382648 2016-12-23
EP16382648.0 2016-12-23
PCT/IB2017/058374 WO2018116281A1 (en) 2016-12-23 2017-12-22 Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Publications (2)

Publication Number Publication Date
BR112019012972A2 BR112019012972A2 (pt) 2019-12-31
BR112019012972B1 true BR112019012972B1 (pt) 2023-04-18

Family

ID=57799523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012972-3A BR112019012972B1 (pt) 2016-12-23 2017-12-22 Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos

Country Status (19)

Country Link
US (2) US11124505B2 (enExample)
EP (1) EP3559010B1 (enExample)
JP (2) JP7294661B2 (enExample)
KR (1) KR102609373B1 (enExample)
CN (1) CN110198945B (enExample)
BR (1) BR112019012972B1 (enExample)
CA (1) CA3046744A1 (enExample)
CY (1) CY1125531T1 (enExample)
DK (1) DK3559010T3 (enExample)
ES (1) ES2926580T3 (enExample)
HR (1) HRP20221067T1 (enExample)
HU (1) HUE059604T2 (enExample)
IL (1) IL267557B (enExample)
LT (1) LT3559010T (enExample)
MX (1) MX379709B (enExample)
PL (1) PL3559010T3 (enExample)
PT (1) PT3559010T (enExample)
SI (1) SI3559010T1 (enExample)
WO (1) WO2018116281A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
HUE071482T2 (hu) 2018-06-06 2025-08-28 Minoryx Therapeutics S L (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
MX2020013182A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.
JP2026500743A (ja) 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ.エレ. レリグリタゾンの最適投薬
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100249988B1 (ko) * 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
ATE447414T1 (de) 2005-02-16 2009-11-15 Micromet Ag Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren
EP2072519A4 (en) * 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
JPWO2008136428A1 (ja) * 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
KR20150003766A (ko) * 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法

Also Published As

Publication number Publication date
IL267557B (en) 2021-10-31
US20190389852A1 (en) 2019-12-26
PT3559010T (pt) 2022-09-01
HUE059604T2 (hu) 2022-11-28
ES2926580T3 (es) 2022-10-27
WO2018116281A1 (en) 2018-06-28
KR102609373B1 (ko) 2023-12-01
HRP20221067T1 (hr) 2022-11-25
US20220204496A1 (en) 2022-06-30
IL267557A (en) 2019-08-29
JP2023052918A (ja) 2023-04-12
KR20190100300A (ko) 2019-08-28
DK3559010T3 (da) 2022-08-15
EP3559010A1 (en) 2019-10-30
PL3559010T3 (pl) 2022-11-21
CN110198945A (zh) 2019-09-03
BR112019012972A2 (pt) 2019-12-31
SI3559010T1 (sl) 2022-10-28
US11731963B2 (en) 2023-08-22
MX379709B (es) 2025-03-11
US11124505B2 (en) 2021-09-21
CN110198945B (zh) 2023-06-27
CY1125531T1 (el) 2026-02-25
LT3559010T (lt) 2022-10-10
MX2019007327A (es) 2019-09-02
JP7294661B2 (ja) 2023-06-20
CA3046744A1 (en) 2018-06-28
EP3559010B1 (en) 2022-06-08
JP2020502228A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
ES2926580T3 (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
US20110312903A1 (en) Fluorination of organic compounds
EP3112340A1 (en) Method for producing 4-borono-l-phenylalanine having 18f atom introduced thereinto, and precursor of 4-borono-l-phenylalanine having 18f atom introduced thereinto
RU2660433C2 (ru) Хиральное 4-боронофенилаланиновое (вра) производное и способ его получения и способ получения 18f-меченного вра с использованием указанного производного
US20220249710A1 (en) Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer
WO2013003734A2 (en) Fluorination of aromatic ring systems
EP2310362A1 (en) Formation of 18f and 19f fluoroarenes bearing reactive functionalities
JP2015523985A (ja) ジアリールヨードニウム塩を製造するための方法及び反応剤
US9434740B2 (en) Taxane compounds, compositions and methods
EP3594200B1 (en) Radioactive fluorine-labeled precursor compound, and method for producing radioactive fluorine-labeled compound using same
CN109415383A (zh) 制备艾日布林的方法及其中间体
CN116457357A (zh) 稠合的三并环衍生物及其在药学上的应用
HK40014767B (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
HK40014767A (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
ES2714628B2 (es) Compuestos derivados de la vitamina D
KR101925650B1 (ko) 결정화에 의한 전구체 화합물의 정제
HK40013289B (en) Process for preparing thiazolidinedione compounds and salts thereof
HK40013289A (en) Process for preparing thiazolidinedione compounds and salts thereof
JP2007031647A (ja) 固相合成を利用した超短半減期核種を含む化合物の製造方法およびそれに用いる化合物
HK1197053A1 (zh) 新型谷氨酸酯衍生物的前体
CN104530111A (zh) 化合物三甲基(3-(三甲基硅基)苄氧基)硅烷及其制备方法和应用
HK1197053B (en) Novel precursors of glutamate derivatives

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2017, OBSERVADAS AS CONDICOES LEGAIS